Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor

Abstract

The invention provides not only a smooth muscle growth inhibitory composition and a composition for inhibiting expression of adhesion molecules in vascular endothelial cells, each comprising the adipose tissue-specific secretory factor apM1 as an active ingredient, but also a method for diagnosis of arteriosclerosis which comprises assaying apM1 in a sample, an antibody against apM1, and a diagnostic kit for arteriosclerosis which comprises the antibody as an active component, all of which contribute to the elucidation of obesity-related genes and corresponding expression products which are useful for the etiologic exploration and establishment of therapeutic modalities for various obesity-related diseases, particularly arteriosclerosis inclusive of angina pectoris and myocardial infarction. By utilizing the information thus obtained, therapeutic and diagnostic methods for various diseases can be established.

1 . A smooth muscle growth inhibitory composition comprising a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.  
     
     
         2 . A prophylactic and therapeutic composition for arteriosclerosis which comprises a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.  
     
     
         3 . A prophylactic and therapeutic composition for post-angioplasty restenoses which comprises a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.  
     
     
         4 . A diagnostic agent for arteriosclerosis which comprises an antibody against the adipose tissue-specific secretory factor apM1.  
     
     
         5 . Hybridoma KOC09108 having an ability to produce a monoclonal antibody against the adipose tissue-specific secretory factor apM1 as deposited under the accession number of FERM BP-6542.  
     
     
         6 . The monoclonal antibody against the adipose tissue-specific secretory factor apM1 as produced by Hybridoma KOCO9108.  
     
     
         7 . A diagnostic kit for arteriosclerosis which comprises an antibody against the adipose tissue-specific factor apM1 as an active component.  
     
     
         8 . A method of inhibiting growth of smooth muscle which comprises administering a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof to a patient in whom a treatment for inhibiting growth of smooth muscle is required.  
     
     
         9 . A method for the prophylaxis and therapy of arteriosclerosis which comprises administering a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof to a patient in whom a treatment for inhibiting growth of smooth muscle is required.  
     
     
         10 . A method for the prophylaxis and therapy of post-angioplasty restenoses which comprises administering a pharmacologically effective amount of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof to a patient in whom a prophylactic or therapeutic treatment for post-angioplasty restenoses is required.  
     
     
         11 . A method for diagnosis of arteriosclerosis which comprises quantitating the adipose tissue-specific secretory factor apM1 in a sample with an antibody against the adipose tissue-specific secretory factor apM1 and comparing the result of the assay with the measured values in healthy subjects and patients with arteriosclerosis to establish a diagnosis of arteriosclerosis.  
     
     
         12 . Use of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof for the manufacture of a smooth muscle growth inhibitory composition.  
     
     
         13 . Use of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof for the manufacture of a prophylactic and therapeutic composition for arteriosclerosis.  
     
     
         14 . Use of at least one member selected from the group consisting of the adipose tissue-specific secretory factor apM1 and a pharmacologically acceptable salt thereof for the manufacture of a prophylactic and therapeutic composition for post-angioplasty restenoses.  
     
     
         15 . Use of an antibody against the adipose tissue-specific secretory factor apM1 for the manufacture of a diagnostic agent for arteriosclerosis.